Literature DB >> 3013246

Enhancer-facilitated expression of prokaryotic and eukaryotic genes using human histone gene 5' regulatory sequences.

F Marashi, S Helms, A Shiels, S Silverstein, D S Greenspan, G Stein, J Stein.   

Abstract

We examined the structural and functional properties of a human H3 histone gene promoter. The complete nucleotide sequence of an H3 structural gene and 515 nucleotides of 5' and 100 nucleotides of 3' flanking sequences were determined. The upstream region of this cell cycle dependent H3 histone gene, designated pST519, contains consensus sequences typical of genes transcribed by RNA polymerase II. To address promoter function directly, we determined the capability of the 5' flanking sequences to direct the transcription of two genes which are not functionally or structurally related. Fusion genes were constructed using the 5' flanking sequences of this human H3 histone gene and either human beta-globin or bacterial chloramphenicol acetyltransferase (CAT) coding sequences. Both of these fusion genes were expressed when transfected into HeLa cells. Under control of the pST519 histone gene promoter, a beta-globin mRNA transcript was initiated at the appropriate H3 (bp) enhancer, inserted upstream from the histone promoter in both fusion constructs, increased levels of beta-globin and CAT expression. Expression of the pST519 H3 histone gene in COS cells in the absence of the SV40 72-bp enhancer confirmed that the sequences required for promoting transcription reside within the 750-bp 5' flanking sequences and that the exogenous enhancer facilitates, but is not a prerequisite for, transcription. Enhancer-facilitated expression of a cell cycle dependent human H4 histone gene was also observed following transfection into mouse L cells and indicates that the regulatory sequences of human histone genes and transcription factors of mouse cells are compatible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013246     DOI: 10.1139/o86-039

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  8 in total

1.  A comprehensive compilation and alignment of histones and histone genes.

Authors:  D Wells; C McBride
Journal:  Nucleic Acids Res       Date:  1989       Impact factor: 16.971

2.  Changes in the stability of a human H3 histone mRNA during the HeLa cell cycle.

Authors:  T D Morris; L A Weber; E Hickey; G S Stein; J L Stein
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

3.  In vivo protein binding sites and nuclease hypersensitivity in the promoter region of a cell cycle regulated human H3 histone gene.

Authors:  U Pauli; S Chrysogelos; H Nick; G Stein; J Stein
Journal:  Nucleic Acids Res       Date:  1989-03-25       Impact factor: 16.971

4.  Two target sites for protein binding in the promoter region of a cell cycle regulated human H1 histone gene.

Authors:  A J van Wijnen; K L Wright; R F Massung; M Gerretsen; J L Stein; G S Stein
Journal:  Nucleic Acids Res       Date:  1988-01-25       Impact factor: 16.971

5.  A nuclear protein with affinity for the 5' flanking region of a cell cycle dependent human H4 histone gene in vitro.

Authors:  A J van Wijnen; J L Stein; G S Stein
Journal:  Nucleic Acids Res       Date:  1987-02-25       Impact factor: 16.971

Review 6.  Modifications in molecular mechanisms associated with control of cell cycle regulated human histone gene expression during differentiation.

Authors:  G S Stein; J L Stein; J B Lian; A J Van Wijnen; K L Wright; U Pauli
Journal:  Cell Biophys       Date:  1989-12

7.  Altered binding of human histone gene transcription factors during the shutdown of proliferation and onset of differentiation in HL-60 cells.

Authors:  G Stein; J Lian; J Stein; R Briggs; V Shalhoub; K Wright; U Pauli; A van Wijnen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  Fine mapping of the human pentraxin gene region on chromosome 1q23.

Authors:  M T Walsh; A Divane; A S Whitehead
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.